Karyopharm Therapeutics (KPTI) Common Equity (2016 - 2025)
Historic Common Equity for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$292.9 million.
- Karyopharm Therapeutics' Common Equity fell 5747.27% to -$292.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$292.9 million, marking a year-over-year decrease of 5747.27%. This contributed to the annual value of -$292.9 million for FY2025, which is 5747.27% down from last year.
- As of Q4 2025, Karyopharm Therapeutics' Common Equity stood at -$292.9 million, which was down 5747.27% from -$269.3 million recorded in Q3 2025.
- Karyopharm Therapeutics' Common Equity's 5-year high stood at -$16.7 million during Q4 2022, with a 5-year trough of -$292.9 million in Q4 2025.
- Moreover, its 5-year median value for Common Equity was -$129.1 million (2021), whereas its average is -$134.6 million.
- In the last 5 years, Karyopharm Therapeutics' Common Equity soared by 7909.45% in 2022 and then tumbled by 71775.94% in 2023.
- Over the past 5 years, Karyopharm Therapeutics' Common Equity (Quarter) stood at -$79.7 million in 2021, then surged by 79.09% to -$16.7 million in 2022, then plummeted by 717.76% to -$136.2 million in 2023, then crashed by 36.57% to -$186.0 million in 2024, then tumbled by 57.47% to -$292.9 million in 2025.
- Its Common Equity stands at -$292.9 million for Q4 2025, versus -$269.3 million for Q3 2025 and -$238.9 million for Q2 2025.